搡老女人多毛老妇女中国,日韩亚洲欧美中文高清在线,人妻少妇一区二区三区,色妞色综合久久夜夜,日本熟妇xxxx

Your Good Partner in Biology Research

  1. 首頁
  2. 試劑盒
  3. 酶聯(lián)免疫試劑盒
  4. Human insulin-like growth factors binding protein 3,IGFBP-3 ELISA Kit

Human insulin-like growth factors binding protein 3,IGFBP-3 ELISA Kit

  • 中文名稱：
    人胰島素樣生長因子結(jié)合蛋白3(IGFBP-3)酶聯(lián)免疫試劑盒
  • 貨號：
    CSB-E04590h
  • 規(guī)格：
    96T/48T
  • 價格：
    ￥3200/￥2500
  • 其他：

產(chǎn)品詳情

  • 產(chǎn)品描述：
    人胰島素樣生長因子結(jié)合蛋白3(IGFBP-3)酶聯(lián)免疫試劑盒（CSB-E04590h）為雙抗夾心法ELISA試劑盒，定量檢測血清、血漿、組織勻漿樣本中的IGFBP3含量。IGFBP3（胰島素樣生長因子結(jié)合蛋白-3）是一種在人體中編碼的蛋白質(zhì)，主要功能是延長IGF-1和IGF-2的半衰期，并阻止它們與細(xì)胞表面受體的相互作用。IGFBP3在調(diào)節(jié)IGF信號通路中發(fā)揮重要作用，其表達(dá)水平與多種疾病，包括癌癥的發(fā)生和發(fā)展密切相關(guān)。研究IGFBP3的機(jī)制有助于理解其在疾病過程中的作用，并為開發(fā)新的治療策略提供依據(jù)。試劑盒檢測范圍為0.78 ng/mL-50 ng/mL，靈敏度為0.195 ng/mL。本產(chǎn)品適用于基礎(chǔ)醫(yī)學(xué)研究，如探究 IGF 信號通路在代謝調(diào)控、腫瘤微環(huán)境或組織修復(fù)中的作用機(jī)制，支持科研人員對血液樣本或組織提取物中 IGFBP - 3 的動態(tài)變化進(jìn)行系統(tǒng)性分析。本品僅用于科研，不用于臨床診斷，產(chǎn)品具體參數(shù)及操作步驟詳見產(chǎn)品說明書。
  • 別名：
    Acid stable subunit of the 140 K IGF complex ELISA Kit; Binding protein 29 ELISA Kit; Binding protein 53 ELISA Kit; BP 53 ELISA Kit; BP53 ELISA Kit; Growth hormone dependent binding protein ELISA Kit; IBP 3 ELISA Kit; IBP-3 ELISA Kit; IBP3 ELISA Kit; IBP3_HUMAN ELISA Kit; IGF binding protein 3 ELISA Kit; IGF-binding protein 3 ELISA Kit; IGFBP 3 ELISA Kit; IGFBP-3 ELISA Kit; IGFBP3 ELISA Kit; Insulin Like Growth Factor Binding Protein 3 ELISA Kit; Insulin-like growth factor binding protein 3 precursor ELISA Kit; Insulin-like growth factor-binding protein 3 ELISA Kit
  • 縮寫：
  • Uniprot No.：
  • 種屬：
    Homo sapiens (Human)
  • 樣本類型：
    serum, plasma, tissue homogenates
  • 檢測范圍：
    0.78 ng/mL-50 ng/mL
  • 靈敏度：
    0.195 ng/mL
  • 反應(yīng)時間：
    1-5h
  • 樣本體積：
    50-100ul
  • 檢測波長：
    450 nm
  • 研究領(lǐng)域：
    Signal Transduction
  • 測定原理：
    quantitative
  • 測定方法：
    Sandwich
  • 精密度：
    Intra-assay Precision (Precision within an assay): CV%<8%      
    Three samples of known concentration were tested twenty times on one plate to assess.  
    Inter-assay Precision (Precision between assays): CV%<10%      
    Three samples of known concentration were tested in twenty assays to assess.    
                 
  • 線性度：
    To assess the linearity of the assay, samples were spiked with high concentrations of human IGFBP-3 in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
    　 Sample Serum(n=4)  
    1:10 Average % 92  
    Range % 82-103  
    1:20 Average % 95  
    Range % 91-99  
    1:40 Average % 95  
    Range % 90-100  
    1:80 Average % 91  
    Range % 85-100  
  • 回收率：
    The recovery of human IGFBP-3 spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
    Sample Type Average % Recovery Range  
    Serum (n=5) 98 92-106  
    EDTA plasma (n=4) 95 90-100  
                 
                 
  • 標(biāo)準(zhǔn)曲線：
    These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
    ng/ml OD1 OD2 Average Corrected  
    50 2.119 2.119 2.119 1.957  
    25 1.560 1.521 1.541 1.379  
    12.5 1.012 1.080 1.046 0.884  
    6.25 0.716 0.726 0.721 0.559  
    3.12 0.471 0.454 0.463 0.301  
    1.56 0.321 0.334 0.328 0.166  
    0.78 0.235 0.243 0.239 0.077  
    0 0.161 0.163 0.162 　  
  • 數(shù)據(jù)處理：
  • 貨期：
    3-5 working days

產(chǎn)品評價

靶點(diǎn)詳情

  • 最新研究進(jìn)展：
    IGFBP3的最新研究發(fā)現(xiàn)，它可能參與了肝臟疾病的發(fā)生和發(fā)展。一項研究發(fā)現(xiàn)，肝臟細(xì)胞中IGFBP3表達(dá)的下調(diào)可能與肝纖維化和肝硬化的發(fā)展有關(guān)。此外，IGFBP3還被發(fā)現(xiàn)可以作為胃癌的潛在生物標(biāo)記物，可以用于胃癌的早期診斷和治療。
  • 功能：
    IGF-binding proteins prolong the half-life of the IGFs and have been shown to either inhibit or stimulate the growth promoting effects of the IGFs on cell culture. They alter the interaction of IGFs with their cell surface receptors. Also exhibits IGF-independent antiproliferative and apoptotic effects mediated by its receptor TMEM219/IGFBP-3R. Inhibits the positive effect of humanin on insulin sensitivity. Promotes testicular germ cell apoptosis.
  • 基因功能參考文獻(xiàn)：
    1. In cancerous tissues of colorectal cancer (CRC) patients, the miR197 level was inversely correlated with the expression of IGFBP3, which indicated that miR197 may modulate cell migration and invasion by targeting IGFBP3 in CRC patients. PMID: 30106114
    2. Together findings presented here recognize an inherent role of MTA1 as a modifier of DNMT3a and IGFBP3 expression, and consequently, the role of MTA1-DNMT3a-IGFBP3 axis in breast cancer progression. PMID: 28393842
    3. B-Myb is an independent prognostic marker and serves as a potential target in the diagnosis and/or treatment of NSCLC, and that B-Myb functions as a tumor-promoting gene by targeting IGFBP3 in NSCLC cells. PMID: 29772705
    4. IGFBP-3 up-regulates PI3K/Akt/mTOR signaling pathway and down-regulates autophagy during cell aging. The decrease of IGFBP-3 expression in senescence and cell aging by H2O2 leads to up-regulation of mTOR and p53 signaling pathway, suggesting that IGFBP-3 could play a key role as an aging marker PMID: 29579543
    5. Low IGFBP-3 serum levels were associated with Pancreatic Cancer. PMID: 28681154
    6. IGFBP-3 Interacts with the Vitamin D Receptor in Insulin Signaling Associated with Obesity in Visceral Adipose Tissue PMID: 29112142
    7. IGFBP3, a gene associated with preeclampsia pathophysiology, was validated as a target gene of miR-210 PMID: 28653360
    8. analysis of IGFBP3-IGF1 correlation with the risk of esophageal carcinoma; the free form of IGFBP3, might be inversely associated with esophageal cancer incidence PMID: 28596684
    9. Our data indicate that targeting IGFBP-3-dependent signaling pathways through gefitinib-FTY720 co-therapy may be effective in many basal-like breast cancers, and suggest tissue IGFBP-3 and CD44 measurement as potential biomarkers of treatment efficacy. PMID: 28778177
    10. Laboratory models corroborate intertumor heterogeneity of endocrine response in HGSOC but identify features associated with functional ERalpha and endocrine responsiveness. Assessing ERalpha function (e.g., IGFBP3 expression) in conjunction with H-score may help select patients who would benefit from endocrine therapy. Preclinical data suggest that SERDs might be more effective than tamoxifen PMID: 28073843
    11. In longitudinal analysis, changes of FGF-21 were not significantly related to changes of height, IGF-1 or IGFBP-3 in obese children. PMID: 26887040
    12. the concentrations of insulin, IGF-1, IGFBP-3 and their association with prostate size in patients with BPH PMID: 28300542
    13. We confirmed a previously reported association between circulating IGFBP-3 and diabetes risk in the older adult population PMID: 29040592
    14. The results of this study, while not clearly supporting associations between these obesity-related biomarkers and renal cell carcinoma risk, are consistent with previously reported findings for adiponectin, and suggest an association with elevated IGFBP-3 among obese individuals PMID: 28484923
    15. our results reveal a new function of IGFBP2, providing a novel insight into the mechanism of adipogenic differentiation and identifying a potential target mediator for improving adipose tissue engineering based on Wharton's jelly of the umbilical cord (WJCMSCs). PMID: 28859160
    16. Increased IGFBP3 level as associated with decreased risk of frailty in men. PMID: 28609827
    17. Functional IGFBP-3 was significantly lower in postmenopausal women than in premenopausal women, for both patients with rheumatoid arthritis and controls. There was a significant decrease in plasma functional IGFBP-3 levels in postmenopausal RA in comparison to healthy premenopausal subjects. PMID: 27775453
    18. study suggests high-order interactions of the IGFBP-3 rs2854744 AA genotype, BMI>/=24kg/m2, and DISI<9.85 mg/day on increased BC risk, particularly among postmenopausal women PMID: 27631779
    19. The stratification of individuals by gender revealed that Slovak males carrying IGFBP-3 G alleles (G32G or GG) had marginally increased risk for developing MDD as compared to CC homozygous males (p=0.09). In women, inverse association was observed between SNP rs1042522 and MDD risk (p=0.04 for recessive model). PMID: 27755861
    20. results indicate that hypoxia suppresses the osteogenic differentiation of mesenchymal stem cells via IGFBP3 up-regulation. PMID: 27563882
    21. Meta-analysis suggests that for esophageal cancer, the low IGFBP-3 level is associated with high cancer risk, poor prognosis, and unfavorable tumor stage and metastasis. [meta-analysis] PMID: 27978831
    22. Expression of IL-24 and IGFBP-3 significantly suppressed prostate cancer tumor growth in vivo. PMID: 26323436
    23. Blood IGFBP3 was lower in Black participants compared to Whites. PMID: 27455178
    24. The microRNA-125b level promotes invasive ability in p53-mutated cells via PI3K/AKT activation by targeting of insulin-like growth factor-binding protein-3. PMID: 28378642
    25. High expression of IGFBP3 is associated with metastasis in nasopharyngeal carcinoma. PMID: 27658775
    26. results indicated that miR-197 targeted IGFBP3 to induce the overgrowth and anti-apoptotic effects of Wilms tumor cells PMID: 27223680
    27. There is no interaction between IGFBP3 and MTA1 in ESCC, and they are not independent risk factors for esophageal squamous cell carcinoma prognosis. PMID: 27035126
    28. Insulin-like growth factor binding protein-3 is a new predictor of radiosensitivity on esophageal squamous cell carcinoma PMID: 26670461
    29. Study showed that IGFBP3 is dramatically induced in pancreatic tumors, and is abundantly produced in pancreatic cancer cells, causing muscle wasting through both impaired myogenesis via, at least, inhibition of IGF/PI3K/AKT signaling. PMID: 26975989
    30. Insulin-like growth factor-independent insulin-like growth factor binding protein 3 promotes cell migration and lymph node metastasis of oral squamous cell carcinoma cells via integrin beta1 signaling. PMID: 26540630
    31. endogenous IGFBP-3 is a p53 target that plays a role in breast cancer cell responsiveness to DNA damaging therapy PMID: 26378048
    32. Data indicate that IGF-binding protein 3 (IGFBP3) and F3 gene expression levels in formalin fixed paraffin embedded (FFPE) prostate cancer tissue would provide an improved survival prediction for prostate cancer patients. PMID: 26731648
    33. calcineurin in astrocytes was activated by Amyloid beta, leading to IGFBP-3 release. PMID: 26637371
    34. Circulating levels of IGF-1, IGFBP-3 and their molar ratio were not associated with the risk of occurrence of colorectal adenoma PMID: 26388613
    35. Independent of obesity, high insulin levels but reduced levels of IGFBP-3 were associated with increased lung cancer risk in current smokers. PMID: 27071409
    36. IGFBP-3 levels after ischemic stroke may independently predict functional outcome after one year. PMID: 26069074
    37. -202 A/C IGFBP3 polymorphisms did not show any consistent association with clinical and laboratory features of acromegalic patients even after treatment. PMID: 25552351
    38. polymorphism in IGFBP-3 rs2854744 A>C might be a potential predictor of esophageal squamous cell carcinoma risk and patient survival PMID: 26349977
    39. Humanin Peptide Binds to Insulin-Like Growth Factor-Binding Protein 3 (IGFBP3) and Regulates Its Interaction with Importin-beta. PMID: 26216267
    40. Authors demonstrate that IGFBP3 is a direct TAp73alpha (the p73 isoform that contains the trans-activation domain) target gene and activates the expression of IGFBP3 in actively proliferating cells. PMID: 26063735
    41. Methylation of IGFBP-3 in colorectal cancer was identified to be significantly associated with risk of recurrence. PMID: 25822686
    42. Data indicate that IGF binding protein-3 (IGFBP-3) reduced transcription of a variety of integrins, especially integrin beta4. PMID: 25945837
    43. Serum IGFBP3 was increased in hepatocellular carcinoma patients compared to patients with liver cirrhosis, but lower than in healthy controls. PMID: 26068014
    44. The current meta-analysis suggests that the IGFBP-3 C2133G polymorphism may confer susceptibility to colorectal cancer. [Meta-analysis] PMID: 25966104
    45. In women with normal somatotroph function, IGFBP3 levels do not change in the first trimester of pregnancy. PMID: 25179796
    46. Loss of IGFBP3 expression is associated with Colorectal Cancer. PMID: 25987030
    47. IGFBP-3 polymorphism is not a cause of delayed infancy-childhood transition in idiopathic short stature children. PMID: 25742716
    48. The functional IGFBP3 A-202C polymorphism may influence the susceptibility and progression of breast cancer in the Chinese population. PMID: 25960224
    49. Results suggest that immediately postexercise testosterone and IGFPB-3 responses are significantly increased after endurance training followed by strength training but not after strength training followed by endurance training. PMID: 25028991
    50. These findings indicate that IGFBP-3 enhances etoposide-induced cell growth inhibition by blocking the NF-kappaB signaling pathway in gastric cancer cells. PMID: 25662950

    顯示更多

    收起更多

  • 亞細(xì)胞定位：
    Secreted.
  • 組織特異性：
    Expressed by most tissues. Present in plasma.
  • 數(shù)據(jù)庫鏈接：

    HGNC: 5472

    OMIM: 146732

    KEGG: hsa:3486

    STRING: 9606.ENSP00000370473

    UniGene: Hs.450230